Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5-HT1B/1D receptor agonist) presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults, providing rapid relief of headache and associated symptoms.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent product availability and regulatory support across multiple regions.

Imigran (sumatriptan) belongs to the triptan class and is used to treat acute migraine and related headache disorders. - Migraine with aura: provides rapid relief of headache, nausea, and photophobia. - Migraine without aura: reduces pain intensity and associated symptoms within two hours. - Acute cluster headache attacks: alleviates severe unilateral head pain during an episode.

Sumatriptan may cause a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Nausea or dry mouth Serious or Rare Side Effects: - Coronary artery spasm leading to chest pain - Severe allergic reaction such as anaphylaxis - Serotonin syndrome when combined with other serotonergic agents - Hypertension or myocardial infarction

Before prescribing Imigran, clinicians should evaluate several safety considerations. - Cardiovascular assessment: screen for history of coronary artery disease, uncontrolled hypertension, or cerebrovascular disorders. - Concomitant serotonergic drugs: avoid use with MAO inhibitors or other triptans to reduce serotonin syndrome risk. - Ergotamine derivatives: do not combine with ergotamine or dihydroergotamine due to additive vasoconstriction. - Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction. - Pregnancy and lactation: assess risk‑benefit; use only if clearly needed. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Sumatriptan can interact with several medicines, altering its safety or effectiveness. Major Interactions (Avoid): - MAO inhibitors (e.g., phenelzine, tranylcypromine): increase risk of serotonin syndrome. - Other triptans or ergotamine derivatives: additive vasoconstriction may cause serious cardiovascular events. - SSRIs, SNRIs, or other serotonergic agents: heightened potential for serotonin syndrome. - Certain antihypertensives (e.g., ergot alkaloids): may potentiate vasoconstrictive effects. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma levels. - Antihypertensive beta‑blockers: may affect blood pressure response. - Oral contraceptives: may slightly increase migraine frequency, requiring monitoring.